Hereditary neuropathic amyloidosis – Diagnostics – Overview of Information and Clinical Research

Understanding hereditary neuropathic amyloidosis begins with proper diagnosis, a process that can be challenging due to the variety of symptoms and their similarity to other conditions. Early detection through specific tests and careful monitoring can help guide treatment decisions and improve the management of this progressive genetic disorder.

Introduction: Who Should Undergo Diagnostics

Hereditary neuropathic amyloidosis, also known as hereditary transthyretin amyloidosis or ATTRv amyloidosis, is a rare genetic condition that often takes years to diagnose correctly. The journey to diagnosis can be long and frustrating, with many patients visiting multiple doctors before receiving the right answer. Understanding when to seek diagnostic testing can make a significant difference in how quickly someone receives proper care.^[8]

People who should consider undergoing diagnostics for this condition include those who experience unusual symptoms such as numbness or tingling in their feet and hands, unexplained weight loss, digestive problems like chronic diarrhea or constipation, or episodes of dizziness when standing up. These symptoms might seem unrelated at first, but they can be early signs of nerve damage caused by abnormal protein deposits building up in the body. If you notice these symptoms developing gradually and without another clear cause, it is important to discuss them with your doctor.^[1]

Family history plays a crucial role in determining who should be tested. Because this form of amyloidosis is inherited, anyone who has a blood relative diagnosed with ATTRv amyloidosis should seriously consider genetic testing and regular monitoring. The condition follows an autosomal dominant pattern, which means if one parent carries the genetic mutation, there is a 50 percent chance their child will inherit it. However, not everyone who inherits the mutation will develop symptoms, making monitoring programs especially valuable.^[3]

In areas where this disease is more common, such as Portugal, Japan, Sweden, and parts of Brazil, screening programs for family members of affected individuals are often in place. These programs help identify people who carry the genetic mutation before they develop symptoms, allowing for earlier intervention. In the United States, African Americans should be particularly aware of this condition, as certain genetic variants that cause hereditary amyloidosis are more common in people of African descent.^[6]

⚠️ Important

If you have unexplained symptoms like numbness in your hands and feet, difficulty walking, recurring digestive problems, or unexplained heart issues, and especially if someone in your family has been diagnosed with hereditary amyloidosis, you should speak with your doctor about diagnostic testing. Early diagnosis can help you access treatments that may slow the progression of the disease.

People who experience carpal tunnel syndrome in both hands at the same time, particularly at a younger age than usual, should also consider testing for hereditary amyloidosis. While carpal tunnel syndrome is common and usually not related to amyloidosis, when it appears in both hands simultaneously or is accompanied by other unexplained symptoms, it can be an early warning sign of protein deposits affecting the nerves.^[15]

Anyone experiencing heart problems such as unexplained thickening of the heart wall, irregular heartbeats, or symptoms of heart failure without typical risk factors should also be evaluated. Sometimes the cardiac form of hereditary amyloidosis can be the first presentation of the disease, particularly in certain genetic variants. Heart symptoms combined with any degree of nerve problems should prompt consideration of amyloidosis testing.^[5]

Diagnostic Methods to Identify the Disease

Diagnosing hereditary neuropathic amyloidosis involves multiple steps and different types of tests. The process typically begins when a doctor suspects the condition based on symptoms and medical history. Confirming the diagnosis requires finding evidence of amyloid deposits in the body and identifying a genetic mutation in the TTR gene, which provides instructions for making the transthyretin protein.^[1]

One of the most common initial diagnostic procedures is a tissue biopsy. This involves taking a small sample of tissue from the body to examine under a microscope for the presence of amyloid deposits. The location of the biopsy depends on which part of the body is showing symptoms. An abdominal fat pad biopsy is frequently used because it is relatively simple and minimally invasive. During this procedure, a doctor removes a small amount of fat tissue from the abdomen through a needle. This sample is then examined to see if abnormal protein deposits are present.^[9]

Other tissues that may be biopsied include the gastrointestinal tract, particularly if someone is experiencing digestive symptoms. A biopsy can be taken during an endoscopy or colonoscopy. In some cases, biopsies of the skin, nerves, kidneys, or heart may be necessary to confirm organ involvement and identify amyloid deposits. Each type of biopsy provides valuable information about where amyloid has accumulated in the body.^[15]

After amyloid is found in a tissue sample, doctors need to determine what type of protein is forming the amyloid deposits. This is critical because different proteins cause different types of amyloidosis, and each type requires different treatment. Two main laboratory techniques are used for this purpose: immunohistochemistry and mass spectrometry. Immunohistochemistry uses special antibodies to identify the specific protein, while mass spectrometry is a more advanced technique that can precisely identify the protein composition of the amyloid deposits. These tests help distinguish hereditary transthyretin amyloidosis from other forms such as AL amyloidosis, which is caused by a different protein.^[9]

Genetic testing is essential for confirming the diagnosis of hereditary amyloidosis. A simple blood test can identify whether someone has a mutation in the TTR gene. There are more than 120 different known mutations in this gene, and each can cause slightly different patterns of disease. The genetic test will specify which variant someone carries, which helps doctors predict how the disease might progress and which organs are most likely to be affected. For example, the V30M variant is commonly found in Portugal, Japan, and Sweden and typically causes symptoms related to nerve damage, while the V122I variant is more common in African Americans and often affects the heart.^[7]

Blood tests are also used to check overall health and organ function. Doctors typically order tests to measure kidney function, liver enzymes, thyroid hormones, and various proteins in the blood. These tests help assess whether organs are being damaged by amyloid deposits. Blood tests can also reveal anemia or other abnormalities that might accompany the disease.^[8]

Neurological testing plays a crucial role in evaluating the extent of nerve damage. Doctors perform detailed physical examinations to check sensation, muscle strength, reflexes, and coordination. Nerve conduction studies and electromyography (EMG) measure how well nerves and muscles are working. In these tests, small electrodes are placed on the skin, and mild electrical signals are used to measure nerve signals. These tests can show whether nerves are damaged and help distinguish this condition from other types of neuropathy.^[4]

Testing for autonomic dysfunction is important because hereditary amyloidosis often affects the nerves that control automatic body functions. Tests might include measuring blood pressure while lying down and then standing up to check for abnormal drops in blood pressure. Other tests can assess sweating patterns, heart rate variability, and digestive function. These tests help doctors understand how severely the autonomic nervous system is affected.^[14]

Heart evaluation is essential in the diagnostic process. An echocardiogram uses sound waves to create images of the heart and can show if the heart wall has thickened or if the heart is not pumping effectively. An electrocardiogram (ECG or EKG) records the electrical activity of the heart and can detect abnormal rhythms or conduction problems. These are common findings in people with cardiac amyloidosis.^[6]

Advanced imaging techniques can help identify amyloid deposits in the heart without requiring a biopsy. Cardiac MRI (magnetic resonance imaging) can show characteristic patterns in the heart muscle that suggest amyloid deposits. Additionally, specialized nuclear medicine scans using specific radioactive tracers can detect transthyretin amyloid deposits in the heart. These scans have become increasingly valuable because they can help distinguish ATTR amyloidosis from AL amyloidosis without needing a heart biopsy.^[9]

Eye examinations are also part of the diagnostic workup. Hereditary amyloidosis can affect the eyes in several ways, causing problems such as vitreous opacity (clouding of the gel inside the eye), dry eyes, glaucoma, or changes in the pupils. An ophthalmologist can perform specialized examinations to check for these issues and document the extent of eye involvement.^[1]

Kidney function tests include both blood and urine analyses. Blood tests measure levels of creatinine and other substances that indicate how well the kidneys are filtering waste. Urine tests can detect protein in the urine, called proteinuria, which indicates kidney damage. The amount and type of protein found in urine can provide clues about the severity of kidney involvement.^[8]

Diagnostics for Clinical Trial Qualification

When someone with hereditary neuropathic amyloidosis considers enrolling in a clinical trial to test new treatments, they must undergo specific diagnostic tests to determine if they qualify. Clinical trials have strict criteria, called inclusion and exclusion criteria, which help ensure that the study participants are appropriate for the treatment being tested and that results will be meaningful.^[10]

The first requirement for most clinical trials is documented genetic confirmation of a TTR gene mutation. Participants must have blood test results showing they carry a pathogenic variant in the TTR gene. The genetic test report needs to specify which mutation is present, as some trials may focus on specific genetic variants while others accept any pathogenic TTR mutation.^[11]

Trials typically require evidence of amyloid deposits through biopsy. Participants need to have had a tissue biopsy that confirmed the presence of amyloid, and the protein type must have been identified as transthyretin through immunohistochemistry or mass spectrometry. Some trials accept biopsies from several years earlier, while others may require more recent confirmation. The documentation must show clear evidence that amyloid deposits are present and that they are made of transthyretin protein.^[12]

Disease stage assessment is critical for trial enrollment. Clinical trials often target specific stages of disease progression. Many trials recruit people with early-stage disease who have relatively mild symptoms, while others may focus on those with more advanced disease. Researchers use standardized scoring systems to classify disease stage. One commonly used system divides disease into stages based on walking ability and the extent of sensory loss. Stage 1 typically means the person can walk without assistance but has some sensory loss. Stage 2 indicates they need one or two walking aids, and Stage 3 means they need a wheelchair or are bedridden.^[8]

Neurological function must be carefully assessed and documented. Trials often use specific measurement scales to evaluate nerve damage objectively. The Neuropathy Impairment Score (NIS) is frequently used, which assigns numerical values to various aspects of nerve function including muscle weakness, sensory loss, and reflexes. Another commonly used tool is the Norfolk Quality of Life Questionnaire for diabetic neuropathy, which assesses how symptoms affect daily life. Baseline scores on these scales help determine eligibility and provide a starting point for measuring whether the experimental treatment helps.^[10]

Heart function evaluation is required for most trials because cardiac involvement is common in hereditary amyloidosis and can affect treatment safety. Participants typically need to undergo an echocardiogram to measure heart function and structure. Key measurements include how much blood the heart pumps with each beat (called ejection fraction) and the thickness of the heart walls. Some trials exclude people with severe heart involvement, while others specifically study treatments for cardiac amyloidosis. Blood tests measuring heart stress markers called NT-proBNP or BNP are also commonly required.^[12]

Laboratory tests provide essential information about organ function and overall health status. Blood tests typically include complete blood counts, kidney function tests (creatinine and estimated glomerular filtration rate), liver function tests (ALT, AST, bilirubin), and thyroid function tests. Many trials have specific cutoff values for these tests. For example, kidney function must be above a certain level for the person to safely participate. These tests are repeated regularly during the trial to monitor for any problems.^[11]

⚠️ Important

Clinical trials have specific requirements for participation, and not everyone with hereditary amyloidosis will qualify for every trial. The tests needed for trial screening are similar to standard diagnostic tests but may be more extensive. If you are interested in participating in research, discuss this with your healthcare team early, as preparing the necessary documentation and completing required tests takes time.

Autonomic function testing may be required to document the extent of autonomic nervous system involvement. Tests measure blood pressure changes when moving from lying to standing, heart rate variability, sweating responses, and gastrointestinal function. Some trials specifically target people with significant autonomic symptoms, while others may exclude those with severe autonomic dysfunction due to safety concerns.^[14]

Nutritional status assessment is often part of trial screening because hereditary amyloidosis can cause significant weight loss and malnutrition. Researchers document body weight, body mass index (BMI), and sometimes perform more detailed nutritional assessments. Many trials require that participants maintain a certain minimum weight or BMI to be eligible, as severe malnutrition can complicate treatment and affect study outcomes.^[12]

Quality of life questionnaires are standard tools in clinical trials. Participants complete detailed surveys about how symptoms affect their daily activities, emotional well-being, and overall life satisfaction. These patient-reported outcomes are important because they capture aspects of disease impact that medical tests cannot measure. Common questionnaires used in amyloidosis trials include the Norfolk Quality of Life-Diabetic Neuropathy questionnaire and various functional assessment scales.^[12]

Walking tests and physical performance measures help objectively assess functional ability. The 6-minute walk test measures how far someone can walk in six minutes and provides information about physical capacity and endurance. Grip strength measurements, timed standing tests, and balance assessments may also be included. These functional measures are important endpoints in clinical trials because they reflect real-world abilities that matter to patients.^[20]

Previous treatment history must be thoroughly documented. Trials need to know what treatments participants have received, including any disease-modifying medications, liver transplantation, or other interventions. Some trials require that participants be treatment-naive (never treated), while others may allow enrollment after previous therapies have failed or been completed. The timing of previous treatments is also important, as some trials require a certain period to pass after stopping other medications.^[10]

Imaging studies beyond echocardiography may be required depending on the trial. Cardiac MRI can provide detailed information about heart structure and function. Specialized nuclear medicine scans can detect and quantify amyloid deposits in the heart. For trials focusing on neurological aspects, nerve conduction studies and electromyography document the baseline extent of nerve damage.^[20]

Prognosis and Survival Rate

Prognosis

The outlook for people with hereditary neuropathic amyloidosis varies considerably depending on several factors. The specific genetic mutation someone carries plays a major role in determining how the disease will progress. Some mutations cause symptoms to appear earlier in life and progress more rapidly, while others result in later onset and slower progression. Geographic location and ethnic background also influence prognosis, as certain mutations are more common in specific populations and may behave differently.

The age when symptoms first appear significantly affects long-term outcomes. People who develop symptoms in their third or fourth decade, particularly those from areas where the disease is common such as Portugal and Japan, often experience faster progression than those whose symptoms begin later in life. Early-onset disease, especially before age 50, tends to be associated with more severe autonomic and sensory nerve involvement.

The organs affected by amyloid deposits also impact prognosis. When the heart is significantly involved, with restrictive cardiomyopathy causing heart failure, the outlook tends to be more concerning. Cardiac involvement is a major factor affecting survival. Similarly, severe kidney damage requiring dialysis or significant gastrointestinal problems leading to severe malnutrition can complicate the disease course and affect outcomes.

The availability of disease-modifying treatments has changed the prognosis for many patients. Medications that reduce the production of abnormal transthyretin protein or stabilize the protein to prevent it from forming deposits can slow disease progression. Early diagnosis and prompt initiation of treatment generally lead to better outcomes. People who begin treatment when they have only mild symptoms tend to maintain better function longer than those who wait until more advanced stages to start therapy.

Without treatment, hereditary neuropathic amyloidosis typically progresses steadily. The rate of progression varies but generally leads to increasing disability over several years. Nerve damage worsens gradually, affecting both sensory and motor functions. Walking becomes more difficult, and eventually many people require mobility aids. Autonomic problems such as digestive issues, blood pressure irregularities, and bladder dysfunction tend to worsen over time and can significantly impact quality of life.

Survival rate

Survival in hereditary transthyretin amyloidosis depends on multiple factors including the specific gene mutation, age of onset, organs involved, and access to treatment. Historical data from before modern treatments became available showed that median survival after symptom onset ranged from about 5 to 15 years, with significant variation based on the specific mutation and clinical presentation. Early-onset disease in endemic areas often progressed more rapidly.

Cardiac involvement is the strongest predictor of survival. People who develop significant cardiac amyloidosis with heart failure symptoms generally have shorter survival times than those with primarily neurological involvement. The presence of severe cardiac dysfunction, as measured by tests showing reduced heart function or elevated cardiac stress markers, indicates a more concerning prognosis.

The introduction of liver transplantation in the 1990s improved outcomes for some patients, particularly those with certain genetic variants who received transplants early in their disease course. However, liver transplantation outcomes vary, and the procedure has significant risks. More recently, newer medications including gene-silencing therapies and protein stabilizers have provided treatment options that can slow disease progression without requiring major surgery. These newer treatments appear to be improving survival rates, though long-term data is still being collected.

Nutritional status strongly influences survival. Significant weight loss and malnutrition, often resulting from gastrointestinal involvement, are associated with poorer outcomes. Maintaining adequate nutrition through dietary modifications, nutritional support, and management of digestive symptoms is an important part of care that can affect survival.

Regular monitoring and comprehensive medical management of complications improve outcomes. People who receive care from multidisciplinary teams experienced in treating amyloidosis, with attention to heart, kidney, eye, and neurological problems, tend to have better survival rates than those without specialized care. Early detection and treatment of complications such as heart rhythm problems, infections, or kidney dysfunction can prevent life-threatening events.

#1 Clinical Trials Search in Europe